November 30, 2016 - By Peter Erickson · 0 Comments
The stock of Cardiome Pharma Corporation Ord (NASDAQ:CRME) registered an increase of 40.51% in short interest. CRME’s total short interest was 143,600 shares in November as published by FINRA. Its up 40.51% from 102,200 shares, reported previously. With 31,300 shares average volume, it will take short sellers 5 days to cover their CRME’s short positions. The short interest to Cardiome Pharma Corporation Ord’s float is 0.53%. About 58,201 shares traded hands. CARDIOME PHARMA CORP (NASDAQ:CRME) has declined 39.16% since April 27, 2016 and is downtrending. It has underperformed by 44.39% the S&P500.
Cardiome Pharma Corp. is a specialty pharmaceutical company. The company has a market cap of $88.51 million. The Firm is engaged in the development and commercialization of cardiovascular therapies for heart disease. It currently has negative earnings. The Company’s divisions are Europe and Rest of World.
Insitutional Activity: The institutional sentiment increased to 2.71 in 2016 Q2. Its up 1.15, from 1.56 in 2016Q1. The ratio is positive, as 4 funds sold all CARDIOME PHARMA CORP shares owned while 5 reduced positions. 6 funds bought stakes while 8 increased positions. They now own 12.02 million shares or 5.19% less from 12.67 million shares in 2016Q1.
Jpmorgan Chase & has invested 0% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME). Pnc Service Group Inc accumulated 0% or 35,580 shares. Geode Capital Mgmt Lc accumulated 12,725 shares or 0% of the stock. Renaissance Technologies Ltd holds 0% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME) for 90,213 shares. Citadel Advisors Ltd Limited Liability Company holds 0% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME) for 16,077 shares. Ardsley Advisory Partners holds 0.03% or 28,900 shares in its portfolio. Clarivest Asset Mgmt Ltd Llc accumulated 0% or 21,187 shares. Wells Fargo & Mn accumulated 0% or 700 shares. Putnam Ltd Liability Corp accumulated 2.88 million shares or 0.04% of the stock. Deutsche Bancorp Ag holds 0% or 400 shares in its portfolio. Bankshares Of America Corp De owns 45 shares or 0% of their US portfolio. Royal Bancorporation Of Canada has 0% invested in the company for 15,816 shares. Clough Ptnrs Ltd Partnership has 0.56% invested in the company for 2.06 million shares. One Trading L P holds 0% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME) for 683 shares. Alphaone Investment Serv Ltd accumulated 1.1% or 580,365 shares.
Out of 4 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Cardiome Pharma Corp has been the topic of 7 analyst reports since August 11, 2015 according to StockzIntelligence Inc. LB Securities reinitiated the stock with “Buy” rating in Friday, August 14 report. On Friday, March 11 the stock rating was maintained by Brean Capital with “Buy”. Mackie downgraded it to “Hold” rating and $3.50 target price in Wednesday, October 12 report. The firm earned “Speculative Buy” rating on Friday, May 6 by Mackie. Zacks downgraded the shares of CRME in a report on Tuesday, August 11 to “Buy” rating. H.C. Wainwright initiated the shares of CRME in a report on Wednesday, June 1 with “Buy” rating. The rating was downgraded by Zacks to “Hold” on Wednesday, August 26.
Cardiome Pharma Corp. (Cardiome), incorporated on March 1, 2009, is a specialty pharmaceutical company. The Firm is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s divisions are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.
More recent CARDIOME PHARMA CORP (NASDAQ:CRME) news were published by: Marketwatch.com which released: “Cardiome Pharma Corp.” on December 21, 2009. Also Quotes.Wsj.com published the news titled: “News Cardiome Pharma Corp.CRME” on February 12, 2011. Streetinsider.com‘s news article titled: “Cardiome Pharma (CRME) Moves Closer to XYDALBA Launch in the UK” with publication date: November 29, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Peter Erickson